Erudio Healtherudio.com
Drug
Anastrozole trials: what clinicians said in public
No HCP commentary report on a trial studying anastrozole yet. Erudio has found public clinician commentary on 21 clinical trials studying anastrozole, including PATINA, RxPONDER, SERENA-4 and TAILORx. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PATINA NCT02947685 · Alliance Foundation Trials, LLC. DeepView → | hormone receptor-positive, HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||
| TAILORx NCT00310180 · National Cancer Institute (NCI) DeepView → | hormone receptor-positive HER2-negative node-negative breast cancer | Phase 3 | Deep | View | |||
| RxPONDER NCT01272037 · National Cancer Institute (NCI) DeepView → | Not given | Phase 3 | Deep | View | |||
| SERENA-4 NCT04711252 · AstraZeneca DeepView → | ER-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| RIGHT Choice NCT03839823 · Novartis Pharmaceuticals DeepView → | premenopausal or perimenopausal HR-positive HER2-negative advanced breast cancer | Phase 2 | Deep | View | |||
| MONALEESA-7 NCT02278120 · Novartis Pharmaceuticals DeepView → | premenopausal HR-positive HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| CAMBRIA-2 NCT05952557 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| EMBER-4 NCT05514054 · Eli Lilly and Company DeepView → | ER+, HER2- early breast cancer | Phase 3 | Deep | View | |||
| CAMBRIA-1 NCT05774951 · AstraZeneca DeepView → | ER+/HER2- early breast cancer | Phase 3 | Deep | View | |||
| SERENA-6 NCT04964934 · AstraZeneca DeepView → | ESR1-mutated ER-positive HER2-negative metastatic breast cancer | Phase 3 | Deep | View | |||
| PREcoopERA NCT05896566 · ETOP IBCSG Partners Foundation DeepView → | premenopausal ER-positive/HER2-negative early breast cancer | Phase 2 | Deep | View | |||
| RAMP 301 NCT06072781 · Verastem, Inc. DeepView → | recurrent low-grade serous ovarian cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast08 NCT04556773 · AstraZeneca DeepView → | HER2-low metastatic breast cancer | Phase 1 | Deep | View | |||
| TREAT ctDNA NCT05512364 · European Organisation for Research and Treatment of Cancer - EORTC DeepView → | ER+/HER2- breast cancer with ctDNA relapse | Phase 3 | Deep | View | |||
| TRAK-ER NCT04985266 · Royal Marsden NHS Foundation Trust StandardView → | ER-positive HER2-negative breast cancer with molecular relapse | Phase 2 | Standard | View | |||
| neoMONARCH NCT02441946 · Eli Lilly and Company StandardView → | postmenopausal HR+/HER2- early-stage breast cancer | Phase 2 | Standard | View | |||
| AMBRE NCT04158362 · UNICANCER StandardView → | high burden ER+/HER2- breast cancer with visceral metastasis | Phase 3 | Standard | View | |||
| EvoPAR-Breast01 NCT06380751 · AstraZeneca StandardView → | first-line BRCA1/BRCA2/PALB2-mutated HR-positive HER2-negative advanced breast cancer | Phase 3 | Standard | View | |||
| NCT05501704 NCT05501704 · Jose Pablo Leone FocusedView → | male breast cancer | Phase 2 | Focused | View | |||
| MONARCH 3 NCT02246621 · Eli Lilly and Company FocusedView → | first-line HR+/HER2- advanced breast cancer | Phase 3 | Focused | View | |||
| AMALEE NCT03822468 · Novartis Pharmaceuticals FocusedView → | first-line HR-positive HER2-negative advanced breast cancer | Phase 2 | Focused | View | |||